Brian A Fox

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/775408/publications.pdf

Version: 2024-02-01

26 papers

8,891 citations

16 h-index 25 g-index

29 all docs 29 docs citations

times ranked

29

9767 citing authors

#	Article	IF	CITATIONS
1	Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. International Journal of Hematology, 2022, 115, 222-232.	1.6	15
2	A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Blood Advances, 2022, 6, 2219-2229.	5.2	40
3	A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Blood Advances, 2022, 6, 2207-2218.	5.2	24
4	Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma. Scientific Reports, 2021, 11, 16460.	3.3	3
5	Blood transcriptomic discrimination of bacterial and viral infections in the emergency department: a multi-cohort observational validation study. BMC Medicine, 2020, 18, 185.	5.5	20
6	Integrative network modeling reveals mechanisms underlying T cell exhaustion. Scientific Reports, 2020, 10, 1915.	3.3	14
7	Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. PLoS Medicine, 2020, 17, e1003323.	8.4	33
8	Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 903-913.	5.6	87
9	Genome sequence of a diabetes-prone rodent reveals a mutation hotspot around the ParaHox gene cluster. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 7677-7682.	7.1	30
10	Depletion of regulatory T cells leads to an exacerbation of delayed-type hypersensitivity arthritis in C57BL/6 mice that can be counteracted by IL-17 blockade. DMM Disease Models and Mechanisms, 2016, 9, 427-40.	2.4	10
11	Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model. Arthritis Research and Therapy, 2016, 18, 28.	3.5	6
12	Applying genetics in inflammatory disease drug discovery. Drug Discovery Today, 2015, 20, 1176-1181.	6.4	6
13	High-Resolution Gene Expression Profiling Using RNA Sequencing in Patients With Inflammatory Bowel Disease and in Mouse Models of Colitis. Journal of Crohn's and Colitis, 2015, 9, 492-506.	1.3	57
14	Detection of gene expression signatures related to underlying disease and treatment in rheumatoid arthritis patients. Modern Rheumatology, 2013, 23, 729-740.	1.8	11
15	Increased serum \hat{I}^2 2-microglobulin is associated with clinical and immunological markers of disease activity in systemic lupus erythematosus patients. Lupus, 2012, 21, 1098-1104.	1.6	34
16	Vstm3 is a member of the CD28 family and an important modulator of Tâ€eell function. European Journal of Immunology, 2011, 41, 902-915.	2.9	285
17	Generation of a high-affinity Fc receptor by Ig-domain swapping between human CD64A and CD16A. Protein Engineering, Design and Selection, 2010, 23, 299-309.	2.1	4
18	The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. Journal of Experimental Medicine, 2009, 206, 1495-1503.	8.5	566

#	Article	IF	CITATIONS
19	The Role of Genomic Data in the Discovery, Annotation and Evolutionary Interpretation of the Interferon-Lambda Family. PLoS ONE, 2009, 4, e4933.	2.5	68
20	Cytokine–receptor pairing: accelerating discovery of cytokine function. Nature Reviews Drug Discovery, 2004, 3, 160-170.	46.4	33
21	IL-28, IL-29 and their class II cytokine receptor IL-28R. Nature Immunology, 2003, 4, 63-68.	14.5	1,385
22	X-Ray Diffraction Analysis of Three-Dimensional Crystals of Bovine Rhodopsin Obtained from Mixed Micelles. Journal of Structural Biology, 2000, 130, 73-80.	2.8	176
23	Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor. Science, 2000, 289, 739-745.	12.6	5,486
24	Improved recognition of native-like protein structures using a combination of sequence-dependent and sequence-independent features of proteins., 1999, 34, 82-95.		389
25	Identification of the Calcium Binding Site and a Novel Ytterbium Site in Blood Coagulation Factor XIII by X-ray Crystallography. Journal of Biological Chemistry, 1999, 274, 4917-4923.	3.4	98
26	Improved recognition of nativeâ€like protein structures using a combination of sequenceâ€dependent and sequenceâ€independent features of proteins. Proteins: Structure, Function and Bioinformatics, 1999, 34, 82-95.	2.6	9